Articles Related to Prostate Cancer

A Caucasian male with prostate cancer under androgen deprivation therapy after radiotherapy for a locally advanced lesion. Positron emission tomography/Computed Tomography revealed an adrenal lesion. The mass was removed, and histopathological examination showed adenocarcinoma of prostatic origin. Prostate-specific antigen decreased dramatically after adrenalectomy

View complete article: PDF  |  Full-text

IGRT combined with three-dimensional conformal radiation therapy (3D CRT) and intensity-modulated radiation therapy (IMRT) is gaining quick acceptance in radiotherapy treatment of prostate cancer [1-4]. The advantage of this technique is that it localizes the target volume accurately, thus increasing precision in treatment delivery.

View complete article: PDF  |  Full-text

The first patient was a 77 year old man who had been on abiraterone for 12 months before his phosphorous was checked. At that point, it was 0.6 mg/dl, which is severely decreased. A full work up for hypophosphatemia showed normal parathyroid hormone and 25-hydroxyvitamin D. A urine study showed inappropriate excretion of phosphorous along with aminoaciduria and normoglycemic glucosuria.

View complete article: PDF  |  Full-text

The purpose of this study is to synthesize and characterize nanodroplets, loaded with docetaxel for treatment of prostate cancer under MR-guided focused ultrasound. Water insoluble docetaxel encapsulated in nanodroplets is expected to be delivered into tumors with greater efficiency while minimizing drug related systemic toxicities when used in combination with focused ultrasound. The sequence of our studies toward development and characterization of docetaxel-loaded nanodroplets is as follows. First, we developed methods for synthesis of ultrasound-responsive, docetaxel-loaded nanodroplets (Doc-nd) by a solid dispersion technique. Secondly, we characterized Doc-nd by its morphology and size distributions using a dynamic light scattering (DLS) method.

View complete article: PDF  |  Full-text

A 53 year old man with a background of castrate-sensitive prostate cancer on intermittent androgen deprivation therapy (ADT) presented with right sixth nerve palsy secondary to a solitary right petroclival lesion involving adjacent dura and bone. The clinical and imaging characteristics of the lesion were consistent with a number of differential diagnoses (including metastatic prostate cancer, meningioma and chondrosarcoma).

View complete article: PDF  |  Full-text